Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.
about
Bridging academic science and clinical research in the search for novel targeted anti-cancer agentsManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceUnderstanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyAnalysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia.
P2860
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@ast
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@en
type
label
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@ast
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@en
prefLabel
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@ast
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@en
P2860
P356
P1433
P1476
Managing chronic myeloid leuke ...... sine kinase inhibitor therapy.
@en
P2093
D J Deangelo
P2860
P2888
P356
10.1038/BCJ.2012.30
P577
2012-10-19T00:00:00Z